Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition

Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United 
States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc. 
MONTREAL, April 22, 2013 /CNW/ - Valeant Pharmaceuticals International, Inc. 
(NYSE: VRX and TSX: VRX) announced that the applicable waiting period under 
the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect 
to the previously announced tender offer by its indirect wholly-owned 
subsidiary, Odysseus Acquisition Corp. ("Purchaser"), for all of the 
outstanding shares of common stock of Obagi Medical Products, Inc. (NASDAQ: 
OMPI) ("Obagi") at a price of $24.00 per share, net to the seller in cash, 
without interest (less any required withholding taxes) and subsequent merger 
of Purchaser with Obagi expired at 11:59 p.m., New York City time April 19, 
2013.  The expiration of the HSR waiting period satisfies one of the 
conditions to consummate the tender offer. 
The completion of the tender offer is also conditioned on approval of the 
transactions by the Antimonopoly Committee of Ukraine (the "AMC") for purposes 
of compliance with applicable Ukrainian antimonopoly law and the tender of a 
majority of the outstanding shares of common stock of Obagi (on a fully 
diluted basis).  A joint application seeking approval of the tender offer and 
subsequent merger was submitted by Valeant and Obagi to the AMC on March 26, 
2013. Although there can be no guarantee or assurance, Valeant believes it is 
possible that the parties may receive approval from the AMC in the near 
future. Valeant expects to complete the tender offer and consummate the merger 
promptly after the AMC's approval of the acquisition is received. 
About Valeant Pharmaceuticals International, Inc. 
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational 
specialty pharmaceutical company that develops, manufactures and markets a 
broad range of pharmaceutical products primarily in the areas of neurology, 
dermatology and branded generics.  More information about Valeant 
Pharmaceuticals International, Inc. can be found at www.valeant.com. 
Forward Looking Statements 
This press release contains forward-looking statements regarding, among other 
things, the proposed acquisition by Valeant of Obagi, satisfaction of closing 
conditions and the timing of closing.  Statements including words such as 
"believes," "expects," "anticipates," "intends," "estimates," "plan," "will," 
"may," "intend," "guidance" or similar expressions are forward-looking 
statements.  Because these statements reflect Valeant's current views, 
expectations and beliefs concerning future events, these forward-looking 
statements involve risks and uncertainties. Investors should note that many 
factors could affect the proposed business combination of the companies and 
could cause actual results to differ materially from those expressed in 
forward-looking statements contained in this press release. These factors 
include, but are not limited to: the risk that the acquisition will not close 
when expected or at all; the risk that Valeant's business and/or Obagi's 
business will be adversely impacted during the pendency of the acquisition; 
the risk that the operations of the two companies will not be integrated 
successfully; and other risks and uncertainties, including those detailed from 
time to time in the companies' periodic reports filed with the Securities and 
Exchange Commission ("SEC") and in the case of Valeant, the Canadian 
Securities Administrators ("CSA"), including current reports on Form 8-K, 
quarterly reports on Form 10-Q and annual reports on Form 10-K, particularly 
the discussion under the caption "RISK FACTORS" in their annual reports on 
Form 10-K for the year ended December 31, 2012, which have been filed with the 
SEC and in the case of Valeant, the CSA. The forward-looking statements in 
this press release are qualified by these risk factors. These are factors 
that, individually or in the aggregate, could cause the companies' actual 
results to differ materially from expected and historical results. The 
companies assume no obligation to publicly update any forward-looking 
statements, whether as a result of new information, future developments or 
otherwise. 
Additional Information and Where to Find It 
This press release is neither an offer to purchase nor a solicitation of an 
offer to sell shares of Obagi. Valeant filed a Tender Offer Statement on 
Schedule TO with the U.S. Securities and Exchange Commission on March 26, 
2013, as amended on April 4, 2013, April 5, 2013 and April 12, 2013. Obagi 
filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect 
to the offer on March 26, 2013, as amended on April 2, 2013, April 3, 2013, 
April 4, 2013, April 5, 2013 and April 12, 2013.   Stockholders and other 
investors are urged to read the tender offer materials (including the Offer to 
Purchase, a related Letter of Transmittal and certain other offer documents) 
and the Solicitation/Recommendation Statement, in each case as amended (to the 
extent applicable), because they contain important information which should be 
read carefully before any decision is made with respect to the tender offer. 
The Offer to Purchase, the related Letter of Transmittal and certain other 
offer documents, as well as the Solicitation/Recommendation Statement, have 
been made available to all stockholders of Obagi at no expense to them. The 
Tender Offer Statement and the Solicitation/Recommendation Statement are 
available for free at the Commission's web site at www.sec.gov. In addition, 
the tender offer statement and other documents that Valeant files with the SEC 
are and will be made available to all stockholders of Obagi free of charge at 
www.valeant.com. The Solicitation/Recommendation Statement and the other 
documents filed by Obagi with the SEC are, and will be, made available to all 
stockholders of Obagi free of charge at www.obagi.com. 
Contact Information:  Laurie W. Little  949-461-6002  laurie.little@valeant.com 
(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO) 
http://www.valeant.com 
http://www.obagi.com 
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO 
PRN Photo Desk, photodesk@prnewswire.com 
SOURCE: Valeant Pharmaceuticals International, Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/April2013/22/c7328.html 
CO: Valeant Pharmaceuticals International, Inc.
ST: Quebec
NI: FIN HEA MNA NEWSTK  
-0- Apr/22/2013 12:01 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.